Roche acquires the rest of Foundation Medicine for $2.4B, supporting its precision medicine strategy

It’s the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma’s drug development business, particularly in cancer treatment.

More From BioPortfolio on "Roche acquires the rest of Foundation Medicine for $2.4B, supporting its precision medicine strategy"